Chronic back pain, estimated to affect 26 million Americans, has recently been linked to blockage of blood vessels supplying the lower back, leading to a condition referred to as lumbar ischemia.
The patients will receive CardioVascular BioTherapeutics' (CVBT's) new drug candidate, which Vascu-Grow as its active ingredient, for lumbar ischemia.
The multi-site clinical study will be performed in Russia and Eastern Europe and will enroll patients who have proven blockages in their lumbar arteries that leads to poor perfusion and chronic pain in their lower backs.
“Our new clinical collaboration with bioRASI in patients with blocked lumbar arteries is a natural extension of our ongoing clinical trials with no-option heart patients, who are receiving our drug candidate for advanced atherosclerotic disease of their coronary arteries,” said Dr Thomas Stegmann, co-founder and chief clinical officer of CVBT.
“Whether it is coronary heart disease, vascular consequences of diabetes, stroke, or intestinal ischemia, it is becoming accepted now by the medical community that if you can increase blood flow to the affected tissues the patients' condition should improve,” he continued. “We want to find out if Cardio Vascu-Grow can accomplish this in patients with chronic back pain caused by blocked lumbar arteries.”